2668 related articles for article (PubMed ID: 11015443)
1. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Freeman GJ; Long AJ; Iwai Y; Bourque K; Chernova T; Nishimura H; Fitz LJ; Malenkovich N; Okazaki T; Byrne MC; Horton HF; Fouser L; Carter L; Ling V; Bowman MR; Carreno BM; Collins M; Wood CR; Honjo T
J Exp Med; 2000 Oct; 192(7):1027-34. PubMed ID: 11015443
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
4. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
[TBL] [Abstract][Full Text] [Related]
5. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Blank C; Gajewski TF; Mackensen A
Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
[TBL] [Abstract][Full Text] [Related]
6. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
7. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
Bennett F; Luxenberg D; Ling V; Wang IM; Marquette K; Lowe D; Khan N; Veldman G; Jacobs KA; Valge-Archer VE; Collins M; Carreno BM
J Immunol; 2003 Jan; 170(2):711-8. PubMed ID: 12517932
[TBL] [Abstract][Full Text] [Related]
8. The expanding world of co-stimulation: the two-signal model revisited.
Chambers CA
Trends Immunol; 2001 Apr; 22(4):217-23. PubMed ID: 11274928
[TBL] [Abstract][Full Text] [Related]
9. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
Fife BT; Pauken KE; Eagar TN; Obu T; Wu J; Tang Q; Azuma M; Krummel MF; Bluestone JA
Nat Immunol; 2009 Nov; 10(11):1185-92. PubMed ID: 19783989
[TBL] [Abstract][Full Text] [Related]
10. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes.
Fleischer J; Soeth E; Reiling N; Grage-Griebenow E; Flad HD; Ernst M
Immunology; 1996 Dec; 89(4):592-8. PubMed ID: 9014827
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of T-cell function by PD-1.
Zha Yy; Blank C; Gajewski TF
Crit Rev Immunol; 2004; 24(4):229-37. PubMed ID: 15588223
[TBL] [Abstract][Full Text] [Related]
12. Targeting T cell costimulation in autoimmune disease.
Stuart RW; Racke MK
Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody.
Makrigiannis AP; Musgrave BL; Hoskin DW
J Leukoc Biol; 1999 Nov; 66(5):792-802. PubMed ID: 10577511
[TBL] [Abstract][Full Text] [Related]
14. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
[TBL] [Abstract][Full Text] [Related]
15. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
16. Absence of B7-dependent responses in CD28-deficient mice.
Green JM; Noel PJ; Sperling AI; Walunas TL; Gray GS; Bluestone JA; Thompson CB
Immunity; 1994 Sep; 1(6):501-8. PubMed ID: 7534617
[TBL] [Abstract][Full Text] [Related]
17. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.
Tseng SY; Otsuji M; Gorski K; Huang X; Slansky JE; Pai SI; Shalabi A; Shin T; Pardoll DM; Tsuchiya H
J Exp Med; 2001 Apr; 193(7):839-46. PubMed ID: 11283156
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function.
Hathcock KS; Laszlo G; Pucillo C; Linsley P; Hodes RJ
J Exp Med; 1994 Aug; 180(2):631-40. PubMed ID: 7519245
[TBL] [Abstract][Full Text] [Related]
19. B7-CD28 interaction promotes proliferation and survival but suppresses differentiation of CD4-CD8- T cells in the thymus.
Zheng X; Gao JX; Chang X; Wang Y; Liu Y; Wen J; Zhang H; Zhang J; Liu Y; Zheng P
J Immunol; 2004 Aug; 173(4):2253-61. PubMed ID: 15294937
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
Keir ME; Latchman YE; Freeman GJ; Sharpe AH
J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
